Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 373

1.

Predicting smoking abstinence with biological and self-report measures of adherence to varenicline: Impact on pharmacogenetic trial outcomes.

Peng AR, Schnoll R, Hawk LW Jr, Cinciripini P, George TP, Lerman C, Tyndale RF.

Drug Alcohol Depend. 2018 Jun 26;190:72-81. doi: 10.1016/j.drugalcdep.2018.04.035. [Epub ahead of print]

PMID:
29986268
2.

Transcranial direct current brain stimulation decreases impulsivity in ADHD.

Allenby C, Falcone M, Bernardo L, Wileyto EP, Rostain A, Ramsay JR, Lerman C, Loughead J.

Brain Stimul. 2018 Apr 23. pii: S1935-861X(18)30138-4. doi: 10.1016/j.brs.2018.04.016. [Epub ahead of print]

PMID:
29885858
3.

What a medical school chair wants from the dean.

Hromas R, Leverence R, Mramba LK, Jameson JL, Lerman C, Schwenk TL, Zimmermann EM, Good ML.

J Healthc Leadersh. 2018 May 23;10:33-44. doi: 10.2147/JHL.S158937. eCollection 2018.

4.

A comparison of direct and indirect analytical approaches to measuring total nicotine equivalents in urine.

Taghavi T, Novalen M, Lerman C, George TP, Tyndale RF.

Cancer Epidemiol Biomarkers Prev. 2018 May 31. pii: cebp.0018.2018. doi: 10.1158/1055-9965.EPI-18-0018. [Epub ahead of print]

PMID:
29853480
5.

Leadership Development in Medicine.

Lerman C, Jameson JL.

N Engl J Med. 2018 May 17;378(20):1862-1863. doi: 10.1056/NEJMp1801610. No abstract available.

PMID:
29768144
6.

Amygdala Functional and Structural Connectivity Predicts Individual Risk Tolerance.

Jung WH, Lee S, Lerman C, Kable JW.

Neuron. 2018 Apr 18;98(2):394-404.e4. doi: 10.1016/j.neuron.2018.03.019. Epub 2018 Apr 5.

PMID:
29628186
7.

Improvement of the association between self-reported pill count and varenicline levels following exclusion of participants with misreported pill count: A commentary on Peng et al. (2017).

Peng AR, Le Foll B, Morales M, Lerman C, Schnoll R, Tyndale RF.

Addict Behav. 2018 Apr;79:14-16. doi: 10.1016/j.addbeh.2017.11.032. Epub 2017 Dec 2.

PMID:
29232593
8.

Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism.

Tanner JA, Zhu AZ, Claw KG, Prasad B, Korchina V, Hu J, Doddapaneni H, Muzny DM, Schuetz EG, Lerman C, Thummel KE, Scherer SE, Tyndale RF.

Pharmacogenet Genomics. 2018 Jan;28(1):7-16. doi: 10.1097/FPC.0000000000000317.

PMID:
29232328
9.

Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences.

Chenoweth MJ, Ware JJ, Zhu AZX, Cole CB, Cox LS, Nollen N, Ahluwalia JS, Benowitz NL, Schnoll RA, Hawk LW Jr, Cinciripini PM, George TP, Lerman C, Knight J, Tyndale RF; PGRN-PNAT Research Group.

Addiction. 2018 Mar;113(3):509-523. doi: 10.1111/add.14032. Epub 2017 Nov 2.

PMID:
28921760
10.

Measures and predictors of varenicline adherence in the treatment of nicotine dependence.

Peng AR, Morales M, Wileyto EP, Hawk LW Jr, Cinciripini P, George TP, Benowitz NL, Nollen NL, Lerman C, Tyndale RF, Schnoll R.

Addict Behav. 2017 Dec;75:122-129. doi: 10.1016/j.addbeh.2017.07.006. Epub 2017 Jul 12.

PMID:
28728040
11.

No Effect of Commercial Cognitive Training on Brain Activity, Choice Behavior, or Cognitive Performance.

Kable JW, Caulfield MK, Falcone M, McConnell M, Bernardo L, Parthasarathi T, Cooper N, Ashare R, Audrain-McGovern J, Hornik R, Diefenbach P, Lee FJ, Lerman C.

J Neurosci. 2017 Aug 2;37(31):7390-7402. doi: 10.1523/JNEUROSCI.2832-16.2017. Epub 2017 Jul 10.

12.

Sleep Disturbance During Smoking Cessation: Withdrawal or Side Effect of Treatment?

Ashare RL, Lerman C, Tyndale RF, Hawk LW, George TP, Cinciripini P, Schnoll RA.

J Smok Cessat. 2017 Jun;12(2):63-70. doi: 10.1017/jsc.2016.11. Epub 2016 Apr 12.

13.

Can brain games help smokers quit?: Results of a randomized clinical trial.

Loughead J, Falcone M, Wileyto EP, Albelda B, Audrain-McGovern J, Cao W, Kurtz MM, Gur RC, Lerman C.

Drug Alcohol Depend. 2016 Nov 1;168:112-118. doi: 10.1016/j.drugalcdep.2016.08.621. Epub 2016 Aug 27.

PMID:
27635998
14.

Does cannabis use moderate smoking cessation outcomes in treatment-seeking tobacco smokers? Analysis from a large multi-center trial.

Rabin RA, Ashare RL, Schnoll RA, Cinciripini PM, Hawk LW Jr, Lerman C, Tyndale RF, George TP.

Am J Addict. 2016 Jun;25(4):291-6. doi: 10.1111/ajad.12382. Epub 2016 May 17.

PMID:
27187893
15.

Racial differences in the relationship between rate of nicotine metabolism and nicotine intake from cigarette smoking.

Ross KC, Gubner NR, Tyndale RF, Hawk LW Jr, Lerman C, George TP, Cinciripini P, Schnoll RA, Benowitz NL.

Pharmacol Biochem Behav. 2016 Sep;148:1-7. doi: 10.1016/j.pbb.2016.05.002. Epub 2016 May 11.

16.

Nicotine withdrawal alters neural responses to psychosocial stress.

Ashare RL, Lerman C, Cao W, Falcone M, Bernardo L, Ruparel K, Hopson R, Gur R, Pruessner JC, Loughead J.

Psychopharmacology (Berl). 2016 Jul;233(13):2459-67. doi: 10.1007/s00213-016-4299-5. Epub 2016 Apr 18.

17.

Translational Research on Nicotine Dependence.

Falcone M, Lee B, Lerman C, Blendy JA.

Curr Top Behav Neurosci. 2016;28:121-50. doi: 10.1007/7854_2015_5005. Review.

PMID:
26873019
18.

Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio.

Allenby CE, Boylan KA, Lerman C, Falcone M.

J Neuroimmune Pharmacol. 2016 Sep;11(3):471-83. doi: 10.1007/s11481-016-9656-y. Epub 2016 Feb 12. Review.

19.

Brain Responses to Smoking Cues Differ Based on Nicotine Metabolism Rate.

Falcone M, Cao W, Bernardo L, Tyndale RF, Loughead J, Lerman C.

Biol Psychiatry. 2016 Aug 1;80(3):190-7. doi: 10.1016/j.biopsych.2015.11.015. Epub 2015 Nov 26.

20.

RNA sequencing of transcriptomes in human brain regions: protein-coding and non-coding RNAs, isoforms and alleles.

Webb A, Papp AC, Curtis A, Newman LC, Pietrzak M, Seweryn M, Handelman SK, Rempala GA, Wang D, Graziosa E, Tyndale RF, Lerman C, Kelsoe JR, Mash DC, Sadee W.

BMC Genomics. 2015 Nov 23;16:990. doi: 10.1186/s12864-015-2207-8.

21.

Transcranial Direct Current Brain Stimulation Increases Ability to Resist Smoking.

Falcone M, Bernardo L, Ashare RL, Hamilton R, Faseyitan O, McKee SA, Loughead J, Lerman C.

Brain Stimul. 2016 Mar-Apr;9(2):191-6. doi: 10.1016/j.brs.2015.10.004. Epub 2015 Oct 23.

22.

Decreased Nicotinic Receptor Availability in Smokers with Slow Rates of Nicotine Metabolism.

Dubroff JG, Doot RK, Falcone M, Schnoll RA, Ray R, Tyndale RF, Brody AL, Hou C, Schmitz A, Lerman C.

J Nucl Med. 2015 Nov;56(11):1724-9. doi: 10.2967/jnumed.115.155002. Epub 2015 Aug 13.

23.

Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption.

Bergen AW, Michel M, Nishita D, Krasnow R, Javitz HS, Conneely KN, Lessov-Schlaggar CN, Hops H, Zhu AZ, Baurley JW, McClure JB, Hall SM, Baker TB, Conti DV, Benowitz NL, Lerman C, Tyndale RF, Swan GE; Transdisciplinary Research in Cancer of the Lung Research Team.

PLoS One. 2015 Jul 1;10(7):e0126113. doi: 10.1371/journal.pone.0126113. eCollection 2015.

24.

The Nicotine Metabolite Ratio is Associated With Early Smoking Abstinence Even After Controlling for Factors That Influence the Nicotine Metabolite Ratio.

Chenoweth MJ, Schnoll RA, Novalen M, Hawk LW Jr, George TP, Cinciripini PM, Lerman C, Tyndale RF.

Nicotine Tob Res. 2016 Apr;18(4):491-5. doi: 10.1093/ntr/ntv125. Epub 2015 Jun 11.

PMID:
26069034
25.

Nicotine metabolite ratio (3-hydroxycotinine/cotinine) in plasma and urine by different analytical methods and laboratories: implications for clinical implementation.

Tanner JA, Novalen M, Jatlow P, Huestis MA, Murphy SE, Kaprio J, Kankaanpää A, Galanti L, Stefan C, George TP, Benowitz NL, Lerman C, Tyndale RF.

Cancer Epidemiol Biomarkers Prev. 2015 Aug;24(8):1239-46. doi: 10.1158/1055-9965.EPI-14-1381. Epub 2015 May 26.

26.

Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking.

Tyndale RF, Zhu AZ, George TP, Cinciripini P, Hawk LW Jr, Schnoll RA, Swan GE, Benowitz NL, Heitjan DF, Lerman C; PGRN-PNAT Research Group.

PLoS One. 2015 May 26;10(5):e0128109. doi: 10.1371/journal.pone.0128109. eCollection 2015.

27.

Initial Evaluation of Fenofibrate for Efficacy in Aiding Smoking Abstinence.

Perkins KA, Karelitz JL, Michael VC, Fromuth M, Conklin CA, Chengappa KN, Hope C, Lerman C.

Nicotine Tob Res. 2016 Jan;18(1):74-8. doi: 10.1093/ntr/ntv085. Epub 2015 Apr 20.

28.

Test-Retest Reliability and Stability of the Nicotine Metabolite Ratio Among Treatment-Seeking Smokers.

Hamilton DA, Mahoney MC, Novalen M, Chenoweth MJ, Heitjan DF, Lerman C, Tyndale RF, Hawk LW Jr.

Nicotine Tob Res. 2015 Dec;17(12):1505-9. doi: 10.1093/ntr/ntv031. Epub 2015 Mar 1.

29.

Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial.

Lerman C, Schnoll RA, Hawk LW Jr, Cinciripini P, George TP, Wileyto EP, Swan GE, Benowitz NL, Heitjan DF, Tyndale RF; PGRN-PNAT Research Group.

Lancet Respir Med. 2015 Feb;3(2):131-138. doi: 10.1016/S2213-2600(14)70294-2. Epub 2015 Jan 12.

30.

Working memory-related neural activity predicts future smoking relapse.

Loughead J, Wileyto EP, Ruparel K, Falcone M, Hopson R, Gur R, Lerman C.

Neuropsychopharmacology. 2015 May;40(6):1311-20. doi: 10.1038/npp.2014.318. Epub 2014 Dec 3.

31.

Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers.

Chenoweth MJ, Novalen M, Hawk LW Jr, Schnoll RA, George TP, Cinciripini PM, Lerman C, Tyndale RF.

Cancer Epidemiol Biomarkers Prev. 2014 Sep;23(9):1773-82. doi: 10.1158/1055-9965.EPI-14-0427. Epub 2014 Jul 10.

32.

Applying Quantitative Approaches to the Formative Evaluation of Antismoking Campaign Messages.

Parvanta S, Gibson L, Forquer H, Shapiro-Luft D, Dean L, Freres D, Lerman C, Mallya G, Moldovan-Johnson M, Tan A, Cappella J, Hornik R.

Soc Mar Q. 2013 Dec;19(4):242-264.

33.

Nicotine dependence as a moderator of genetic influences on smoking cessation treatment outcome.

Leventhal AM, Lee W, Bergen AW, Swan GE, Tyndale RF, Lerman C, Conti DV.

Drug Alcohol Depend. 2014 May 1;138:109-17. doi: 10.1016/j.drugalcdep.2014.02.016. Epub 2014 Mar 5.

34.

Large-scale brain network coupling predicts acute nicotine abstinence effects on craving and cognitive function.

Lerman C, Gu H, Loughead J, Ruparel K, Yang Y, Stein EA.

JAMA Psychiatry. 2014 May;71(5):523-30. doi: 10.1001/jamapsychiatry.2013.4091.

35.

An efficient early phase 2 procedure to screen medications for efficacy in smoking cessation.

Perkins KA, Lerman C.

Psychopharmacology (Berl). 2014 Jan;231(1):1-11. doi: 10.1007/s00213-013-3364-6. Epub 2013 Dec 3. Review.

36.

Effects of tolcapone on working memory and brain activity in abstinent smokers: a proof-of-concept study.

Ashare RL, Wileyto EP, Ruparel K, Goelz PM, Hopson RD, Valdez JN, Gur RC, Loughead J, Lerman C.

Drug Alcohol Depend. 2013 Dec 15;133(3):852-6. doi: 10.1016/j.drugalcdep.2013.09.003. Epub 2013 Sep 14.

37.

Evidence from mouse and man for a role of neuregulin 3 in nicotine dependence.

Turner JR, Ray R, Lee B, Everett L, Xiang J, Jepson C, Kaestner KH, Lerman C, Blendy JA.

Mol Psychiatry. 2014 Jul;19(7):801-10. doi: 10.1038/mp.2013.104. Epub 2013 Sep 3.

38.

Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion.

David SP, Strong DR, Leventhal AM, Lancaster MA, McGeary JE, Munafò MR, Bergen AW, Swan GE, Benowitz NL, Tyndale RF, Conti DV, Brown RA, Lerman C, Niaura R.

Addiction. 2013 Dec;108(12):2202-11. doi: 10.1111/add.12325. Epub 2013 Sep 18.

39.

Association of abstinence-induced alterations in working memory function and COMT genotype in smokers.

Ashare RL, Valdez JN, Ruparel K, Albelda B, Hopson RD, Keefe JR, Loughead J, Lerman C.

Psychopharmacology (Berl). 2013 Dec;230(4):653-62. doi: 10.1007/s00213-013-3197-3. Epub 2013 Jul 5.

40.

Neuroimaging in psychiatric pharmacogenetics research: the promise and pitfalls.

Falcone M, Smith RM, Chenoweth MJ, Bhattacharjee AK, Kelsoe JR, Tyndale RF, Lerman C; Pharmacogenomics Research Network Central Nervous System Working Group.

Neuropsychopharmacology. 2013 Nov;38(12):2327-37. doi: 10.1038/npp.2013.152. Epub 2013 Jun 24. Review.

41.

Sensitivity and specificity of a procedure for early human screening of novel smoking cessation medications.

Perkins KA, Lerman C, Karelitz JL, Jao NC, Chengappa KN, Sparks GM.

Addiction. 2013 Nov;108(11):1962-8. doi: 10.1111/add.12273. Epub 2013 Jul 12.

42.

No untoward effects of smoking cues in anti-smoking public service announcements.

Falcone M, Lerman C, Cappella JN, Sanborn P, Jepson C, Strasser AA.

Drug Alcohol Depend. 2013 Nov 1;133(1):279-82. doi: 10.1016/j.drugalcdep.2013.05.006. Epub 2013 Jun 3.

43.

Effects of bupropion on cognitive performance during initial tobacco abstinence.

Perkins KA, Karelitz JL, Jao NC, Gur RC, Lerman C.

Drug Alcohol Depend. 2013 Nov 1;133(1):283-6. doi: 10.1016/j.drugalcdep.2013.05.003. Epub 2013 May 31.

44.

Cognitive function during nicotine withdrawal: Implications for nicotine dependence treatment.

Ashare RL, Falcone M, Lerman C.

Neuropharmacology. 2014 Jan;76 Pt B:581-91. doi: 10.1016/j.neuropharm.2013.04.034. Epub 2013 Apr 29. Review.

45.

Content matters: neuroimaging investigation of brain and behavioral impact of televised anti-tobacco public service announcements.

Wang AL, Ruparel K, Loughead JW, Strasser AA, Blady SJ, Lynch KG, Romer D, Cappella JN, Lerman C, Langleben DD.

J Neurosci. 2013 Apr 24;33(17):7420-7. doi: 10.1523/JNEUROSCI.3840-12.2013.

46.

Biomarkers for smoking cessation.

Bough KJ, Lerman C, Rose JE, McClernon FJ, Kenny PJ, Tyndale RF, David SP, Stein EA, Uhl GR, Conti DV, Green C, Amur S.

Clin Pharmacol Ther. 2013 Jun;93(6):526-38. doi: 10.1038/clpt.2013.57. Epub 2013 Mar 18. Review.

47.

Age-related differences in working memory deficits during nicotine withdrawal.

Falcone M, Wileyto EP, Ruparel K, Gerraty RT, LaPrate L, Detre JA, Gur R, Loughead J, Lerman C.

Addict Biol. 2014 Sep;19(5):907-17. doi: 10.1111/adb.12051. Epub 2013 Mar 18.

48.

The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex.

Zhu AZ, Renner CC, Hatsukami DK, Swan GE, Lerman C, Benowitz NL, Tyndale RF.

Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):708-18. doi: 10.1158/1055-9965.EPI-12-1234-T. Epub 2013 Jan 31.

49.

Nicotinic acetylcholine receptor variation and response to smoking cessation therapies.

Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, Liu J, Lee W, Edlund CK, Hall S, Kwok PY, Benowitz NL, Baker TB, Tyndale RF, Lerman C, Swan GE.

Pharmacogenet Genomics. 2013 Feb;23(2):94-103. doi: 10.1097/FPC.0b013e32835cdabd.

50.

APOE ɛ4, an Alzheimer's disease susceptibility allele, and smoking cessation.

Ashare RL, Karlawish JH, Wileyto EP, Pinto A, Lerman C.

Pharmacogenomics J. 2013 Dec;13(6):538-43. doi: 10.1038/tpj.2012.49. Epub 2012 Dec 18.

Supplemental Content

Loading ...
Support Center